Novartis reports strong meningitis vaccine response

In a head-to-head trial, researchers for Novartis say that the experimental meningitis vaccine Menveo produced a more potent immune response than the standard therapy in use. And other data has underscored that the vaccine is effective in infants not covered by the current vaccine--Menactra. Bacterial meningitis kills about one in ten of its victims and leaves many of the rest deaf or suffering from seizures. In the new study, the Menveo group of 11 to 18-year-olds developed higher levels of antibodies against three of the five subtypes of meningitis and an equal amount of antibodies to a fourth.

"The number of adolescents that achieved protective antibody levels was also higher with the new vaccine," says Colin Marchant, a Boston University pediatrician.

- see this release on the data
- read the report from USA Today

Related Articles:
Novartis meningitis vaccine delivers positive data
Novartis pays big for roster of new vaccines
Novartis plots $700M biotech plant

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.